Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Significance of "Not Detected but Amplified" Results by Real-Time PCR Method for HPV DNA Detection.

Kim TS, Lim MS, Hong YJ, Hwang SM, Park KU, Song J, Kim EC.

Biomed Res Int. 2016;2016:5170419. doi: 10.1155/2016/5170419. Epub 2016 Dec 21.

3.

Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.

Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C.

J Clin Virol. 2013 Sep;58(1):161-7. doi: 10.1016/j.jcv.2013.06.041. Epub 2013 Jul 27.

PMID:
23895930
4.

Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.

Basu P, Banerjee D, Mittal S, Dutta S, Ghosh I, Chowdhury N, Abraham P, Chandna P, Ratnam S.

J Med Virol. 2016 Jul;88(7):1271-8. doi: 10.1002/jmv.24453. Epub 2016 Jan 6.

PMID:
26693677
5.

Detection and genotyping of human papillomavirus by five assays according to cytologic results.

Choi J, Park Y, Lee EH, Kim S, Kim JH, Kim HS.

J Virol Methods. 2013 Jan;187(1):79-84. doi: 10.1016/j.jviromet.2012.09.005. Epub 2012 Sep 13.

PMID:
22982075
6.

Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.

Park Y, Lee E, Choi J, Jeong S, Kim HS.

J Clin Microbiol. 2012 Jul;50(7):2359-65. doi: 10.1128/JCM.00337-12. Epub 2012 Apr 18.

7.

Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?

Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, Iyer VK, Mathur SR, Sreenivas V, Shah KV, Gravitt PE.

Cancer Epidemiol. 2009 Dec;33(6):446-50. doi: 10.1016/j.canep.2009.10.013. Epub 2009 Nov 20.

8.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group.

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

9.

The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens.

Chen W, Jeronimo J, Zhao FH, Qiao YL, Valdez M, Zhang X, Kang LN, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

J Clin Virol. 2014 Dec;61(4):553-7. doi: 10.1016/j.jcv.2014.09.018. Epub 2014 Oct 7.

PMID:
25453572
11.

Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.

Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1394-9.

12.
13.

HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT.

JAMA. 2000 Jan 5;283(1):87-93.

PMID:
10632285
14.

Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.

Kwon MJ, Roh KH, Park H, Woo HY.

J Clin Virol. 2014 Apr;59(4):246-9. doi: 10.1016/j.jcv.2014.01.015. Epub 2014 Jan 30.

PMID:
24568964
15.

Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.

Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C.

J Virol Methods. 2009 Mar;156(1-2):77-83. doi: 10.1016/j.jviromet.2008.11.002. Epub 2008 Dec 17.

PMID:
19041893
16.

Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.

Castle PE, Gutierrez EC, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Vaughan LM, Wheeler CM, Gravitt PE, Schiffman M.

J Clin Microbiol. 2011 Aug;49(8):3029-32. doi: 10.1128/JCM.00422-11. Epub 2011 Jun 1.

17.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
18.

Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.

Broccolo F, Fusetti L, Rosini S, Caraceni D, Zappacosta R, Ciccocioppo L, Matteoli B, Halfon P, Malnati MS, Ceccherini-Nelli L.

J Med Virol. 2013 Mar;85(3):472-82. doi: 10.1002/jmv.23487. Epub 2012 Dec 26.

PMID:
23280876
19.

Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.

Yu S, Kwon MJ, Lee EH, Park H, Woo HY.

J Med Virol. 2015 Sep;87(9):1587-93. doi: 10.1002/jmv.24206. Epub 2015 Apr 24.

PMID:
25914215
20.

Comparison of Abbott RealTime High-Risk HPV and Hybrid Capture 2 Assays for Detection of HPV Infection.

Ko K, Yu S, Lee EH, Park H, Woo HY, Kwon MJ.

Ann Clin Lab Sci. 2016 Sep;46(5):522-8.

PMID:
27650620

Supplemental Content

Support Center